Description
Only 25% of rare SORL1 variants have been functionally characterized for trafficking defects. The clinical utility of sSorLA biomarker for classifying variants of uncertain significance remains to be validated in larger cohorts.
Gap type: open_question Source paper: Soluble SorLA in CSF, a novel biomarker to explore disrupted trafficking of SorLA protein in Alzheimer disease. (2025, Alzheimer’s research & therapy, PMID:40336092)
Evidence summary
{“resolution_pipeline”: “scidex.atlas.gap_closure_pipeline”, “task_id”: “f4f7b129-0f43-4c84-abd8-20d4e701842d”, “evaluated_at”: “2026-04-28T19:10:50.749102+00:00”, “resolution_summary”: “Resolved by hypothesis h-SDA-2026-04-26-gap-20260426-001521-03-csf-plasma-aqp4-polarization-index-as-a-novel-bi-3c3fec6b27: CSF/Plasma AQP4 Polarization Index as a Novel Biomarker of Astrocyte Glymphatic Failure in Early Neurodegeneration. Supporting evidence includes debate sess_SDA-2026-04-15-gap-pubmed-20260411-093843-0a9326c2_20260416-032731.”, “match_counts”: {“hypothesis_matches”: 1, “debate_matches”: 5, “paper_matches”: 0}, “hypothesis_matches”: [{“id”: “h-SDA-2026-04-26-gap-20260426-001521-03-csf-plasma-aqp4-polarization-index-as-a-novel-bi-3c3fec6b27”, “title”: “CSF/Plasma AQP4 Polarization Index as a Novel Biomarker of Astrocyte Glymphatic Failure in Early Neurodegeneration”, “score”: 0.241, “reason”: “5 token overlaps; entity overlap: csf”, “analysis_id”: “SDA-2026-04-26-gap-20260426-001521”, “target_gene”: “AQP4”, “target_pathway”: null, “disease”: null, “composite_score”: 0.7050000000000001, “confidence_score”: 0.498, “status”: “proposed”, “pubmed_evidence_ids”: [“24179313”, “27371494”, “30561329”, “30842439”, “34499128”]}], “debate_matches”: [{“id”: “sess_SDA-2026-04-15-gap-pubmed-20260411-093843-0a9326c2_20260416-032731”, “title”: “The abstract identifies BACE1 as an attractive drug target but doesn’t address its normal physiological roles. Understanding these functions is critical to predict potential adverse effects of BACE1 inhibitors in therapeutic development.\n\nGap type: open_question\nSource paper: BACE1: the beta-secretase enzyme in Alzheimer’s disease. (2004, Journal of molecular neuroscience : MN, PMID:15126696)”, “score”: 0.339, “reason”: “7 token overlaps; entity overlap: pmid”, “analysis_id”: “SDA-2026-04-15-gap-pubmed-20260411-093843-0a9326c2”, “quality_score”: 0.76, “status”: “completed”, “target_artifact_id”: null, “target_artifact_type”: null}, {“id”: “sess_SDA-2026-04-13-gap-pubmed-20260410-165527-8256a071_20260414-013429”, “title”: “The authors explicitly state that the effects of these novel genes (MATR3, CHCHD10, TBK1, TUBA4A, NEK1, C21orf2, and CCNF) have not yet been investigated in animal models. This is critical for understanding pathogenic mechanisms and translating findings to clinical practice.\n\nGap type: open_question\nSource paper: Novel genes associated with amyotrophic lateral sclerosis: diagnostic and clinical implications. (2018, The Lancet. Neurology, PMID:29154141)”, “score”: 0.336, “reason”: “8 token overlaps; entity overlap: pmid”, “analysis_id”: “SDA-2026-04-13-gap-pubmed-20260410-165527-8256a071”, “quality_score”: 0.71, “status”: “completed”, “target_artifact_id”: null, “target_artifact_type”: null}, {“id”: “sess_SDA-2026-04-06-gap-pubmed-20260406-041439-ec89b1e4_task_9aae8fc5”, “title”: “While single-cell sequencing reveals microglial heterogeneity across regions, ages, and sexes, the functional consequences of this diversity remain unclear. Understanding these differences could explain variable disease patterns and inform personalized therapeutic approaches.\n\nGap type: open_question\nSource paper: Beyond Activation: Characterizing Microglial Functional Phenotypes. (2021, Cells, PMID:34571885)”, “score”: 0.324, “reason”: “7 token overlaps; entity overlap: pmid”, “analysis_id”: “SDA-2026-04-06-gap-pubmed-20260406-041439-ec89b1e4”, “quality_score”: 0.73, “status”: “completed”, “target_artifact_id”: null, “target_artifact_type”: null}, {“id”: “sess_SDA-2026-04-08-gap-pubmed-20260406-062202-5c32c50a_task_9aae8fc5”, “title”: “AD patients with TDP-43 pathology show worse cognitive impairment, but how TDP-43 mechanistically contributes to this severity is unknown. Understanding this could identify TDP-43 as a therapeutic target for cognitive preservation in AD.\n\nGap type: unexplained_observation\nSource paper: TDP-43 Pathology in Alzheimer’s Disease. (2021, Mol Neurodegener, PMID:34930382)”, “score”: 0.323, “reason”: “6 token overlaps; entity overlap: pmid”, “analysis_id”: “SDA-2026-04-08-gap-pubmed-20260406-062202-5c32c50a”, “quality_score”: 0.734, “status”: “completed”, “target_artifact_id”: null, “target_artifact_type”: null}, {“id”: “sess_SDA-2026-04-16-gap-pubmed-20260410-192526-f2bbb9ab_20260416-135142”, “title”: “While the study demonstrates dose-response relationships between amyloid levels and outcomes, it doesn’t establish specific threshold values for clinical benefit. Defining these thresholds is critical for treatment optimization and stopping rules in clinical practice.\n\nGap type: open_question\nSource paper: Posttreatment Amyloid Levels and Clinical Outcomes Following Donanemab for Early Symptomatic Alzheimer Disease: A Secondary Analysis of the TRAILBLAZER-ALZ 2 Randomized Clinical Trial. (2025, JAMA neurology, PMID:41082199)”, “score”: 0.315, “reason”: “7 token overlaps; entity overlap: pmid”, “analysis_id”: “SDA-2026-04-16-gap-pubmed-20260410-192526-f2bbb9ab”, “quality_score”: 0.76, “status”: “completed”, “target_artifact_id”: null, “target_artifact_type”: null}], “paper_matches”: []}